Testing version — LOERadar is in active testing. Features and data may change.
NIRAVAM (ALPRAZOLAM) | LOERadar
NIRAVAM
NDA
ALPRAZOLAM | N021726 | UCB INC
4 strengths0 unique patents0 unique exclusivities
PTAB Proceedings
No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board
Hatch-Waxman Litigation
Para IV certification filed but no ANDA patent litigation cases (NOS 835) matched from PACER. Litigation may be pending or filed under a different caption.
Citizen Petitions
No FDA citizen petitions matched from Regulations.gov
Products (4)
Sort:
#001 — 0.25MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
RLD
0 patents0 exclusivities▴
TABLET, ORALLY DISINTEGRATING;ORAL | Approved: Jan 19, 2005
No patent or exclusivity listings for this strength.
#002 — 0.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
RLD
0 patents0 exclusivities▾
TABLET, ORALLY DISINTEGRATING;ORAL | Approved: Jan 19, 2005
#003 — 1MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
RLD
0 patents0 exclusivities▾
TABLET, ORALLY DISINTEGRATING;ORAL | Approved: Jan 19, 2005
#004 — 2MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
RLD
0 patents0 exclusivities▾
TABLET, ORALLY DISINTEGRATING;ORAL | Approved: Jan 19, 2005